TG Therapeutics, Inc. has seen rapid enrolment of ENHANCE study, which could allow simplified dosing regime of IV Briumvi.

Q3 2025 Earnings Call November 17, 2025 8:30 AM ESTCompany ParticipantsScott Harvey - CEO & PresidentBrian Meadows - ...

The top-line results from the study showed that the 3-drugs' synergistic effect has the potential as a new fixed-dose combination treatment, enhancing the effect ...

TruGolf Holdings, Inc. (NASDAQ: TRUG), a leading provider of golf simulator software and hardware, today reported its third ...

Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to ...